Floatz logo

(+)-VINCRISTINE

Ovarian Brenner Tumor

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Ovarian Brenner Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
Gynecologic Oncology Group
Phase 3BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 2B
Urokinase-Derived Peptide A6
Gynecologic Oncology Group
Phase 2B
Elesclomol
GOG Foundation
Phase 2B

View all 18 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →